Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

44 Results

  • AMMP - Addiction Medicine Mentorship Program 2021-22

    Contains 8 Component(s) Includes Multiple Live Events. The next is on 08/03/2021 at 6:00 PM (EDT) Recorded On: 06/03/2021

    This longitudinal, year-long program (May 2021-May 2022) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    This longitudinal, year-long program (May 2021-May 2022) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. 

    This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    Schedule:

    Please watch "The Hungry Heart" prior to 6/3/21.  https://vimeo.com/ondemand/the...

    Dr. Kushner has asked that all mentees view the documentary film "The Hungry Heart" prior to her talk. It's about 90 minutes, and can be rented on Vimeo for $3.99. This should be the only time we ask mentees to spend any money on this program, but if you have issues/questions/concerns, please reach out to Dr. Latronica and we can find an arrangement. She also asked me to mention that some of the language in the documentary (specifically stigmatizing language) likely does not "hold up" in our current environment, but she believes the documentary as a whole is important viewing.

    TimeSpeakerMeeting 1: Introduction (6/3/21)
    6:00-8:00  Marla Kushner, D.O."Addiction 101"
    Short Break   
    8:00-9:00 Whole Group Intro Session

    TimeSpeakerMeeting 2: Harm Reduction (8/3/21)
    6:00-7:00Elizabeth Salisbury-Afshar, M.D.Basics of Harm Reduction 
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 3: Special Considerations in Addiction Medicine (9/1/21)
    6:00-7:00Veronica Ridpath, D.O.Taking a Compassionate Substance Use History
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 4: Opioid Use Disorder (10/6/21)
    6:00-7:00Katherine Grieco, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break
     
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 5: Alcohol Use Disorder (11/3/21)
    6:00-7:00Jon Lepley, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 6: Stimulant Use Disorder (12/1/21)
    6:00-7:00James Latronica, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 7:  Sedative/Hypnotic Use Disorder(2/2/22)
    6:00-7:00Steve Wyatt, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 8: Behavioral Addictions & Project Wrap-Up (3/2/22)
    6:00-7:00Bhavna Bali, M.D.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Independent Project Presentations
    8:00-8:10  


    Student Mentors:

    • Kelly Arnez, DO
    • William Bograkos, DO
    • Anthony Dekker, DO
    • Michael Fox, DO
    • R. Gregory Lande, DO
    • Michael Steelman, DO
    • Jan Widerman, DO

    James Latronica, DO (Moderator)

    AOAAM Board of Trustee

    Program Moderator
    Speaker - December 1, 2021

    James R. Latronica, DO received his medical degree from the Philadelphia College of Osteopathic Medicine. His primary training is in Family Medicine, and he graduated residency from Clarion Hospital, in Clarion, PA. He is currently an Addiction Medicine Fellow at Penn State Hershey Medical Center. He is a past Resident Member of the AOAAM Board of Trustees, and he is honored to now serve as a full member.

    His main areas of academic interest are buprenorphine management in the perioperative period, expanded access to MOUD across all demographics, cannabis research, and U.S. drug and health care policy. He is the Associate Editor the Journal of Addictive Diseases.

    He has a deep interest in activism and advocacy and is a member of the American Society of Addiction Medicine’s Public Policy Committee. He also completed the American Osteopathic Association’s Training In Policy Studies (TIPS) Fellowship. In a non-academic role, he was a Pennsylvania field manager for Vot-ER, a physician-driven voter registration campaign during the 2020 presidential campaign. Three of his policy resolutions have been considered by the AOA House of Delegates, one of which was passed at the 2020 House of Delegates.

    He has significant investment in medical education at various levels, and to that end, he is a member of the Pennsylvania Osteopathic Medical Association’s Grant Development Task Force, he received the Philadelphia College of Osteopathic Medicine’s “PCOM Pillar” recognition for his mentorship activities with medical students, and was a past recipient of the Resident Teacher Award from the Society for Teachers of Family Medicine.

    Summer of 2021 he will be joining UPMC Western Psychiatric Hospital in a clinical role, and the University of Pittsburgh School of Medicine as an Assistant Professor.

    Marla Kushner, DO, FAOAAM

    AOAAM President

    Speaker - June 3, 2021

    Doctor Marla Kushner graduated from the Michigan State University College of Osteopathic Medicine. She completed her family medicine residency at Botsford General Hospital in Farmington Hills, MI and completed an Adolescent Young Adult Medicine Fellowship at Chicago Osteopathic Hospital of Rush Presbyterian St. Luke's Hospital in Chicago. After her fellowship, Dr. Kushner began working with adolescent substance abuse facilities in Chicago and received certification and Addiction Medicine from the American Society of Addiction Medicine and is a distinguished fellow of ASAM. She is a diplomate in American Board of Addiction Medicine. Dr. Kushner received her fellowship in the American College of Osteopathic Family Physicians in March 2013 and is currently medical director of the Addiction Recovery Track at Insight Behavioral Health in Chicago and  two high school-based health centers in Chicago. She has a family medicine practice with a focus on adolescent an addiction medicine. 

    Elizabeth Salisbury-Afshar

    Speaker - August 3, 2021

    Dr. Salisbury-Afshar’s focus is on improving the health and wellbeing of people who use drugs and alcohol. Her work includes individual patient care, clinical teaching, and implementation and evaluation of addiction-related programs. She is board certified in family medicine, addiction medicine, and preventive medicine/general public health.

    Prior to coming to the University of Wisconsin, Dr. Salisbury-Afshar has worked in the public and not for profit sectors. She served as the Medical Director of Behavioral Health Systems Baltimore, where she developed and oversaw the Baltimore City Overdose Prevention Plan, the Opioid Fatality Review Board, and the third-party naloxone distribution program. She subsequently served as the Medical Director of Behavioral Health at the Chicago Department of Public Health, where she created and implemented the Department’s strategy to address the opioid overdose crisis, helped to standardize the way opioid-related morbidity and mortality was tracked and reported, developed provider education learning collaboratives to increase access to medications for opioid use disorder (MOUD) treatment, and supported expansion of naloxone access through funding and educational initiatives. Dr. Salisbury-Afshar also served as the Director of the Center for Addiction Research and Effective Solutions (CARES) at the American Institutes for Research. In this role she worked on a variety of projects ranging from addiction-related public health strategy to the development of technical assistance to expand access to evidence-based addiction treatment.

    Dr. Salisbury-Afshar has over ten years of experience working clinically in federally qualified health centers- providing both primary care and addiction medicine treatment. She currently practices at Access Community Health Centers and as a consulting physician in addiction medicine at UW Hospital. She is Faculty in the UW Addiction Medicine Fellowship Program.

    Veronica Ridpath, DO

    AOAAM Resident - Board of Trustee

    Speaker - September 1, 2021

    My professional interests include community psychiatry, addiction psychiatry, and patient advocacy. I also have a special interest in working with LGBT, alternative, and diverse client populations. Currently serving as the Atrium Health Psychiatry Resident Representative to the NCPA Executive Council as well as Addiction Committee member.

    Katherine Grieco

    Speaker - October 6, 2021

    Dr Katherine Grieco graduated from the University of New England College of Osteopathic Medicine in Biddeford, Maine. She completed her residency in family medicine at St. Joseph Medical Center (now part of Penn State Health) in Reading, PA.  After residency she completed an HIV primary care fellowship at The University of California –San Francisco, followed by an addiction medicine fellowship at Yale School of Medicine. She is the former medical director of South Central Rehabilitation Center in New Haven which houses a detoxification center, methadone maintenance treatment program and an outpatient buprenorphine clinic. She most recently served as the medical director of HAVEN (Health Assistance Intervention & Education Network), the health and wellness monitoring program for healthcare professionals in the state of Connecticut who are facing issues related to substance use, and/or mental health. 

     Currently Dr. Grieco is employed by Hartford Healthcare in Connecticut where she treats patients in a withdrawal management unit, as well as in the MATCH program (Medication Assisted Treatment Closer to Home), an intensive outpatient program for patients with substance use/mental health concerns. She also does addiction medicine consultations for patients with HIV within the Hartford Healthcare Community Care Clinic. Dr. Grieco is dually board-certified in family medicine from the American Osteopathic Board of Family Physicians, and in addiction medicine from the American Board of Preventive Medicine. She is a fellow of the American Society of Addiction Medicine. 

    Jon Lepley, DO

    AOAAM President Elect

    Speaker - November 3, 2021

    Jon Lepley, DO received his medical degree from Lake Erie College of Osteopathic Medicine and he completed his Family Medicine residency training at Heart of Lancaster Regional Medical Center. He is Board Certified by the American Osteopathic Board of Family Physicians, with a Certificate of Added Qualifications in Addiction Medicine. He is a Diplomate of the American Board of Addiction Medicine and he is recognized as a Certified Correctional Health Professional by the National Commission on Correctional Health Care. He has been conferred Fellow status by the American Society of Addiction Medicine.

    Dr. Lepley spent many formative years of practice providing healthcare within the Philadelphia Department of Prisons, wherein he pioneered a program which provides Medication Assisted Treatment to individuals suffering from opioid use disorder. His work in Philadelphia has been recognized by the College of Physicians of Philadelphia Section of Public Health and his program has been presented on a national level, garnering interest from large correctional systems across the country. Dr. Lepley’s clinical interests also include recognition of physician impairment and promotion of physician wellness. In this regard, he volunteers his time to serve on an Advisory Committee for the Pennsylvania Physician Health Program. His current professional role is with Penn Medicine as Medical Director of Addiction Medicine for the Lancaster General Health system.

     

    Stephen Wyatt, DO, FAOAAM

    AOAAM Past President

    Speaker - February 2, 2022

    Steven Wyatt is a Board Certified Psychiatrist with added subspecialty certification in Addiction Psychiatry. He Completed a NIDA clinical research fellowship in addiction psychiatry at Yale School of Medicine. He is a CHS professor of psychiatry and an adjunct clinical faculty member of the University of North Carolina. He is the current chairman of the NC psychiatric Association Addiction Psychiatry Committee and the Vice Chair of the Coalition of Physician Education and Substance Use Disorders a national organization focused on addiction medicine medical school education. He participated in the writing of the ASAM Clinical Guidelines for Office Based Opioid Treatment. He is a clinical expert for both that UNC ECHO for Rural Primary Care MAT in North Carolina and the SAMHSA funded Provider Clinical Support System, PCSS; MAT and MIP projects. 

    Bhavna Bali

    Speaker - March 2, 2022

    Bhavna Bali, MD is an Assistant Professor of Internal Medicine and an Addiction Medicine Specialist at Penn State Health Milton S. Hershey Medical Center. She completed primary training in Internal Medicine at Piedmont Athens Regional Hospital in Athens, Georgia with a prime focus in Primary Care, and then completed her Addiction Medicine Fellowship at Penn State. She received her medical degree (MBBS-Bachelor of Medicine and Bachelor of Surgery) from Government Medical College of Patiala in Punjab, India.

    Her main academic interests are focused on expanding patient access to high quality care and evidence-based medications for substance use disorders across all populations. She has a special interest in quality improvement projects focusing on improving health system protocols in both inpatient and outpatient settings. Her passion is to promote and implement harm reduction methods and to continue working on reducing the stigmas healthcare professionals, society, and patients may have when it comes to substance use disorders. She enjoys teaching and taking part in the education of medical students and residents.

    Dr. Bali remains a member of the American Society of Addiction Medicine and American College of Physicians. She also recently became a member of Vot-ER group, which is a Physician driven voter registration campaign, and is currently completing a Civic Health Fellowship with them.  Outside of medicine Bhavna enjoys dancing, painting, and spending time with her family.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 7/26/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/26/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 7/24/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 07/24/2021 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 6/28/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 06/28/2021 at 8:00 PM (EDT)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    William Morrone, DO, FAOAAM

    Medical Director at Recovery Pathways, principal investigator in a naloxone distribution for Mid-Michigan, Medical Director of 35th Circuit Shiawassee County Drug Court

    Associate Professor of Family and Community Medicine, Michigan State University for 18 years and was Asst. Program Director of Family Medicine at Synergy Medical Education Alliance and liaison in the Department of Psychiatry. He has presented or published in:

    Journal of Addictive Diseases (2015 and 2016), American Journal of Addiction (2013), Substance Abuse (2013), BridgeMI.com 2016-2018 (journalism co-op for setting policy), FoxNews.com (editorial) and CNN.com (news), Weekly medical columns in the Gladwin Record and Courier.

    MLive.com, NPR, Arizona Public Radio, American Public Radio and Michigan Public Radio, Adolescent Addiction from the Conrad Hilton Foundation, CORE REMS as a charter master faculty PCSS monthly training sponsored by SAMHSA/CSAT for 9 yr, MOA/MAOFP news letters; AOA publications & advocacy to recognize addiction medicine

    Dr. Morrone has published a naloxone book for families.  AMERICAN NARCAN (2017)  www.AmericanNarcan.com

    He is triple board certified by the American Board of Addiction Medicine, American College of Osteopathic Family Practitioners and the American Academy of Pain Management. Dr. Morrone was a Ruth Fox faculty for the 42nd ASAM 2011 Medical-Scientific Conference Washington DC and is an active addiction educator and social advocate in pain management.

    Nationally and locally he has contributed numerous didactic pieces on opiates, cannabis dependence, primary care, NAS, state based medical marijuana, non-narcotic pain management to providers in recovery; to the state medical and national societies in this area. He is Deputy Medical Director to the Bay County Health Department and principal investigator on Bay County Heroin Task Force.

    He also holds a graduate degree in toxicology and pharmacology from the University of Missouri at Kansas City, graduate school of pharmacy. He also completed an MPH in Baltimore, MD.

    Most notable to pop culture cable TV news viewers is that he has been on Dr. Drew-HLN, CNN News Room, Nancy Grace-CNN Headline News, Court TV, CNN, Studio “B” FOXNews Channel and MSNBC giving medical opinions on drug addiction or death and the 6 stages of decomposition.  For international overdose awareness day (IOAD) he appeared on 23 TV stations in one day.

    Public service is no stranger to Dr. Morrone as he is a Deputy Chief Medical Examiner, a Diplomat of American College of Forensic Examiners and has been a volunteer firefighter. Dr. Morrone is an aggressive advocate for substance abuse treatment and overdose prevention at the FDA, HHS, SAMHSA and congress.  He also trained at the Armed Forces Institute of Pathology (AFIP) in Maryland.

    Spent 10 years as Medical Director at Hospice of Michigan, leaving hospice to do addiction full time. Dr. Morrone is a graduate of MSU, served his internship in internal medicine in Lansing at Ingham Regional Medical Center and his residency in family medicine at the Michigan State University statewide campus site at Bay Regional Medical Center. http://wwwAmericanNarcan.com.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Q&A Session: Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Recorded On: 04/28/2021

    ORN Webinar Series: This is a follow up Q&A Session: Group Based Opioid Treatment webinar. The webinar "Group Based Opioid Treatment" introduced a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: This is a follow up Q&A Session: Group Based Opioid Treatment webinar. The webinar "Group Based Opioid Treatment"  introduced a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability.

    Goals & Objectives: 

    1. Identify the advantages of implementing a shared medical appointment for prescribing medication for OUD and incorporating group therapy.
    2. Recognize the impact the COVID pandemic has had on substance use disorders.
    3. Understand the benefits and challenges of utilizing telehealth to deliver group treatment.

    Needs Assessment: 

    There is a profound need to expand evidence based treatment for OUD in a manner that is efficient and effective. Providing a group based modality is an innovative way to meet this need. Doing so requires a sound understanding of the processes and particulars of group treatment rather than individual treatment. Furthermore, the COVID epidemic has created many challenges for people with substance use disorders and provision of treatment. An understanding of the unique dynamics of telemedicine delivery in a group format is a way to meet these challenges

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    James H. Berry, DO

    James H. Berry, DO, is an addiction psychiatrist and Chair of the Department of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine. He and his colleagues at WVU have developed innovative community based treatment models in response to the addiction crisis in Appalachia and are actively engaged in novel neuromodulation research related to substance use disorders through WVU’s Rockefeller Neuroscience Institute. 

    Steven Forman, MD, PhD

    Guest Panelist: Steven Forman, MD, PhD, VA, Pittsburgh PA

    Bradley Hoffman, Pharm D

    Guest Panelist: Bradley Hoffman, Pharm D, VA, Marion IL

    Mary-Anne Kowol, MD, FASAM

    Guest Panelist: Mary-Anne Kowol, MD, FASAM, Assistant Professor, Medical College of Wisconsin.

    Randi Sokol, MD, MPH, MMedEd

    Guest Panelist: Randi Sokol, MD, MPH, MMedEd, Family Medicine and Addiction Medicine, Cambridge MA

    Matthew E. Stohs MD

    Guest Panelist: Matthew Eugene Stohs MD, Assistant Professor, Medical College of Wisconsin

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • Group Based Opioid Treatment

    Contains 3 Component(s), Includes Credits Recorded On: 04/21/2021

    ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: This webinar will introduce a group-based format to deliver opioid use disorder (OUD) treatment incorporating medications and psychosocial programming. The number of people in need of OUD treatment continues to woefully outpace the availability of treatment providers. Providing treatment with multiple patients in a group-based setting is a strategy that can markedly expand access. Other benefits include enhancing patient recovery networks, improving provider satisfaction and financial viability.

    Goals & Objectives: 

    1. Identify the advantages of implementing a shared medical appointment for prescribing medication for OUD and incorporating group therapy.
    2. Recognize the impact the COVID pandemic has had on substance use disorders.
    3. Understand the benefits and challenges of utilizing telehealth to deliver group treatment.

    Needs Assessment: 

     There is a profound need to expand evidence based treatment for OUD in a manner that is efficient and effective. Providing a group based modality is an innovative way to meet this need. Doing so requires a sound understanding of the processes and particulars of group treatment rather than individual treatment. Furthermore, the COVID epidemic has created many challenges for people with substance use disorders and provision of treatment. An understanding of the unique dynamics of telemedicine delivery in a group format is a way to meet these challenges

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    James H. Berry, DO

    James H. Berry, DO, is an addiction psychiatrist and Chair of the Department of Behavioral Medicine and Psychiatry at West Virginia University School of Medicine. He and his colleagues at WVU have developed innovative community based treatment models in response to the addiction crisis in Appalachia and are actively engaged in novel neuromodulation research related to substance use disorders through WVU’s Rockefeller Neuroscience Institute. 

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • Q&A Session: Buprenorphine Induction for High Potency Synthetic Opioid Users

    Contains 3 Component(s), Includes Credits Recorded On: 04/14/2021

    ORN Webinar Series: Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: Q&A Session following a presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO)

    Goals & Objectives:

    At the conclusion of this activity participants should be able to:

    1. Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder
    2. Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
    3. Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl 

     Needs Assessment: 

    HPSO are the leading cause of overdose death in the US and minimal empiric data exist to guide treatment decisions. Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    John J. Mariani, MD

    Dr. John Mariani is an Associate Professor of Clinical Psychiatry at the Columbia University Irving Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) of Columbia University Irving Medical Center, which is a facility for conducting substance use disorder pharmacotherapy research. Dr. Mariani maintains a busy private practice in Manhattan and is the Medical Advisor to the Major League Baseball Players Association.

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • Essentials: Stimulant Use Disorder

    Contains 4 Component(s), Includes Credits

    Review the diagnosis of stimulant use disorders.

    Review the diagnosis of stimulant use disorders
    Presentation will focus on:

    • Cocaine
    • Amphetamines
    • Methamphetamines
    • Synthetic Cathinones (Bath Salts)
    • Epidemiology
    • Management

    Goals and Objectives:

    At the conclusion of this activity participants should be able to:

    • Attendees will learn the DSM-5 criteria for diagnosing stimulant use disorders 
    • Attendees will learn about the prevalence of stimulant use disorders 
    • Attendees will learn about evidenced based management interventions for stimulant use disorders

    R. Gregory Lande, DO, FAOAAM

    R. Gregory Lande, DO is a past president of the AOAAM.

    Dr. Lande retired from active duty military service and now practices psychiatry at Walter Reed National Military
    Medical center in Bethesda, MD.
    He is the author of over 100 articles, chapters, and books.

  • Buprenorphine Induction for High Potency Synthetic Opioid Users

    Contains 3 Component(s), Includes Credits Recorded On: 04/07/2021

    ORN Webinar Series: Presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO). This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: Presentation on the use of injectable buprenophrine for the treatment of Opioid Use Disorder (OUD) in patients using Highly Potent Synthetic Opioids (HPSO)

    Goals & Objectives:

    At the conclusion of this activity participants should be able to:

    1. Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder
    2. Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
    3. Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl 

     Needs Assessment: 

    HPSO are the leading cause of overdose death in the US and minimal empiric data exist to guide treatment decisions. Attendees will be gain understanding of the pharmacology of HPSO, understand how current OUD pharmacotherapy interacts with HPSOs, and potential treatment options including long-acting injectable buprenorphine.

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


    John J. Mariani, MD

    Dr. John Mariani is an Associate Professor of Clinical Psychiatry at the Columbia University Irving Medical Center and a Research Psychiatrist at the New York State Psychiatric Institute. Dr. Mariani is the Director of the Substance Treatment and Research Service (STARS) of Columbia University Irving Medical Center, which is a facility for conducting substance use disorder pharmacotherapy research. Dr. Mariani maintains a busy private practice in Manhattan and is the Medical Advisor to the Major League Baseball Players Association.

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.

  • Access to Buprenorphine Treatment for Opioid Use Disorder

    Contains 3 Component(s), Includes Credits Recorded On: 03/24/2021

    ORN Webinar Series: A lecture covering the current landscape of buprenorphine treatment availability and ongoing issues is making this medication available, accessible and sustainable for all in need. This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

    ORN Webinar Series: A lecture covering the current landscape of buprenorphine treatment availability and ongoing issues is making this medication available, accessible and sustainable for all in need.

    Goals & Objectives: 

    1. Review the evidence around buprenorphine treatment for opioid use disorder
    2. Review epidemiology of access to buprenorphine in general population and special interest groups (e.g. justice involved, pregnant women)
    3. Discuss primary barriers to entry and retention in treatment
    4. Review effective models and solutions for expansion of buprenorphine treatment and improved linkage to this type of care, including low threshold and telemedicine models
    5. Discuss issues related to buprenorphine access during the COVID-19 pandemic

    Needs Assessment: 

    Will introduce audience to micro and macro issues around access to life saving opioid use disorder treatment - from stigma to policies around controlled substances. Audience will be introduced to current evidence on the success and remaining gaps in making buprenorphine accessible to those in need, including the roles of physicians in de-stigmatizing opioid use disorder and its treatment and offering this medication to patients in need.

    This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Noa Krawczyk, PhD

    Noa Krawczyk is an assistant professor in the Department of population health at NYU School of Medicine and a member of the center of Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use Epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatments for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies an advancing science that can help inform evidence-based policy Zen practices that reduce harm and promote long term recovery. 

    Brendan Saloner, PhD

    Brendan Saloner, PhD, is an Associate Professor in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. His research focuses on the intersection between health and social policy, particularly on the role of health insurance in promoting access to care, financial protection, and wellness. Dr. Saloner has extensive research focused on the financing, organization, and delivery of mental health and substance use treatment among children, adolescents, and young adults. He is interested in the transformation of public sector behavioral health and primary care health systems under the Affordable Care Act. Dr. Saloner is also interested in applied ethical issues related to equitable health care financing and the design of health insurance.

    Julie Kmiec, DO, FAOAAM (Moderator)

    Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

    Planner & Moderator for this webinar.